These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 5306738)

  • 1. [Chemotherapy of L1210 leukemia: comparison of 7 drugs given either continuously for 20 days, or in a single massive dose, early or late].
    Mathé G; Schwarzenberg L; Hayat M; Schneider M
    Rev Fr Etud Clin Biol; 1968 Dec; 13(10):951-60. PubMed ID: 5306738
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.
    Chello PL; Sirotnak FM
    Cancer Treat Rep; 1981; 65(11-12):1049-53. PubMed ID: 7296551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

  • 4. [L 1210 leukemia, an experimental model for the potentiation of drugs used for acute leukemias].
    Pouillart P; Huong TH; Lhéritier J
    Bull Cancer; 1974; 61(4):509-26. PubMed ID: 4458834
    [No Abstract]   [Full Text] [Related]  

  • 5. An assessment of massive-dose chemotherapy of malignant disease.
    Bergsagel DE
    Can Med Assoc J; 1971 Jan; 104(1):31-6. PubMed ID: 4322068
    [No Abstract]   [Full Text] [Related]  

  • 6. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.
    Skipper HE; Schabel FM; Mellett LB; Montgomery JA; Wilkoff LJ; Lloyd HH; Brockman RW
    Cancer Chemother Rep; 1970 Dec; 54(6):431-50. PubMed ID: 5527023
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
    Scheving LE; Burns ER; Halberg F; Pauly JE
    Chronobiologia; 1980; 7(1):33-40. PubMed ID: 7192203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the sequence of administration of cytoxan and methotrexate on the life-span of L1210 leukemic mice.
    Straus MJ; Mantel N; Goldin A
    Cancer Res; 1972 Feb; 32(2):200-7. PubMed ID: 5058180
    [No Abstract]   [Full Text] [Related]  

  • 9. Formal discussion: the clinical pharmacology of anti-leukemia agents.
    Holland JF
    Cancer Res; 1965 Oct; 25(9):1639-41. PubMed ID: 5295365
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effects of the method of reinduction during the treatment of acute lymphoblastic leukemia].
    Jacquillat C; Weil M; Boiron M
    Therapeutique; 1971 Apr; 47(4):403-5. PubMed ID: 5284341
    [No Abstract]   [Full Text] [Related]  

  • 11. [Investigations in the use of mogramostime (GM-CSF) in patients with acute leukemia].
    Paśnicki M
    Wiad Lek; 1995; 48(1-12):194-7. PubMed ID: 9638239
    [No Abstract]   [Full Text] [Related]  

  • 12. Schedule-dependent synergism of methotrexate and vincristine against murine L1210 leukemia.
    Chello PL; Sirotnak FM; Dorick DM; Moccio DM
    Cancer Treat Rep; 1979; 63(11-12):1889-94. PubMed ID: 526921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variant translocations of 11q23 in infant acute lymphoblastic leukemia (ALL): do outcomes differ from t(4;11)?
    Jakab Z; Balogh E; Karászi E; Kappelmayer J; Kiss C; Oláh E
    Med Pediatr Oncol; 2002 Jul; 39(1):63-5. PubMed ID: 12116086
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy and the life cycle of leukaemic cells. A comparison between the growth characteristics of human acute leukaemia and the murine leukaemia L 1210.
    Benckhuijsen C
    Folia Med Neerl; 1969 Dec; 12(2):74-84. PubMed ID: 4894168
    [No Abstract]   [Full Text] [Related]  

  • 15. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
    Góra-Tybor J; Robak T
    Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [On the rotating (cyclic) therapy of acute leukemias according to the MEPO scheme].
    Oehme J
    Dtsch Med Wochenschr; 1967 Oct; 92(41):1866-9. PubMed ID: 6057145
    [No Abstract]   [Full Text] [Related]  

  • 17. Rationale of chemotherapeutic adjuvant treatment.
    Goldin A
    Arch Geschwulstforsch; 1978; 48(7):627-35. PubMed ID: 736743
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of combination chemotherapy with three drugs.
    Goldin A; Venditti JM; Mantel N; Kline I; Gang M
    Cancer Res; 1968 May; 28(5):950-60. PubMed ID: 5652309
    [No Abstract]   [Full Text] [Related]  

  • 19. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
    Kim K; Blechman WJ; Riddle VG; Pardee AB
    Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.